Company profile for Regenxbio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Through a single administration, our product candidates are designed to provide long-lasting e...
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Through a single administration, our product candidates are designed to provide long-lasting effects, potentially significantly altering the course of disease and delivering improved patient outcomes.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
9600 Blackwell Road, Suite 210, Rockville, MD 20850
Telephone
Telephone
240.552.8181
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

euroPLX 90 Lisbon

Not Confirmed

envelop Contact Supplier

euroPLX 90 Lisbon

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/regenxbio-announces-regulatory-update-on-rgx-121-bla-for-mps-ii-302682941.html

PR NEWSWIRE BIO
10 Feb 2026

https://www.fiercebiotech.com/biotech/fda-rejects-regenxbio-hunter-syndrome-gene-therapy-recently-hit-hold-unrelated-brain-tumor

FIERCE BIOTECH
09 Feb 2026

https://www.biospace.com/drug-development/following-sarepta-woes-others-look-to-unlock-the-next-chapter-in-dmd-treatment

BIOSPACE
09 Feb 2026

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-places-clinical-hold-regenxbios-gene-therapy-trials-2026-01-28/

REUTERS
28 Jan 2026

https://www.statnews.com/2026/01/22/biotech-rare-diseases-regenxbio-cytokinetics/

STATNEWS
22 Jan 2026

https://www.prnewswire.com/news-releases/regenxbio-highlights-key-2026-catalysts-and-announces-positive-long-term-functional-outcomes-in-lead-duchenne-gene-therapy-program-302657988.html

PR NEWSWIRE
11 Jan 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty